Abstract:Hintergrund Obwohl die Insulinpumpentherapie (CSII) derzeit im Vergleich zur Insulininjektionstherapie eine deutlich physiologischere Methode der Insulinsubstitution darstellt, wenden in Deutschland im Vergleich zu anderen Ländern weniger Menschen mit einem Typ-1-Diabetes diese Therapieform an. Eine Bedeutung könnten hierbei psychologische Faktoren wie Erwartungen und Einstellungen gegenüber einer Insulinpumpentherapie zukommen. In dieser nicht-interventionellen Beobachtungsstudie wurden die Einstellungen zur Insulinpumpentherapie erwachsener Insulinpumpenträger 6 Monate nach Neueinstellung mit Erwachsenen mit einer mehrfachen täglichen Insulininjektionstherapie (MDI) verglichen. Methoden Einstellungen zur CSII-Therapie wurden mit dem Insulin Pump Attitudes Questionnaire (IPA-Q) erfasst, sowohl bei Teilnehmern der YES-Studie, einer nicht-interventionellen Post Market Surveillance Study zur Effektivität und Sicherheit der mylife YpsoPump (ohne Hybrid-Closed-Loop Algorithmus (= CSII-Nutzer), als auch bei MDI-Anwendern der IPA-Q-Evaluierungsstudie. Ergebnisse Es wurden die Fragebogendaten von n=191 Teilnehmern (CSII-Nutzer: n=81 Teilnehmer der YES-Studie; MDI-Nutzer: n=110 Teilnehmer der IPA-Q Evaluierungsstudie) ausgewertet. CSII-Nutzer, die eine mylife YpsoPump verwenden, standen 6 Monate nach der Neueinstellung oder Umstellung auf eine CSII-Therapie einer solchen signifikant positiver gegenüber als Nutzer einer MDI-Therapie, während gleichzeitig weniger Nachteile der Insulinpumpentherapie berichtet wurden. Schlussfolgerungen Diese Studie zeigt eine hohe Relevanz psychologischer Faktoren für die Akzeptanz und Implementierung einer Insulinpumpentherapie. Strukturierte Diabetesschulungen für Menschen mit Typ-1-Diabetes und eine gute technische Einweisung bei Personen, die sich für eine Insulinpumpentherapie entschieden haben, können dazu beitragen, unrealistische Erwartungen und inadäquate negative Einstellungen zur Insulinpumpentherapie abzubauen. Background Although insulin pump therapy (CSII) is currently the most physiological method of insulin delivery compared to insulin injection therapy, fewer people with type 1 diabetes in Germany use this form of therapy compared to other countries. Psychological factors such as expectations and attitudes towards insulin pump therapy could play a role in this respect. In this non-interventional observational study, attitudes of insulin pump users 6 months after starting insulin pump therapy respectively after switching to another insulin pump model were compared with those of people on multiple daily insulin injection (MDI) therapy. Methods Attitudes towards CSII therapy were measured using the Insulin Pump Attitudes Questionnaire (IPA-Q), both in participants of the YES study, a non-interventional post market surveillance study on the effectiveness and safety of the mylife YpsoPump without hybrid-closed-loop algorithm (= CSII users), and in MDI users of the IPA-Q evaluation study. Results The questionnaire data of n=191 participants (CSII users: n=81 participants of the YES study; MDI users: n=110 participants of the IPA-Q evaluation study) were analyzed. CSII users using a mylife YpsoPump were significantly more positive about CSII therapy 6 months after starting or switching to CSII therapy than MDI users, while fewer disadvantages of insulin pump therapy were reported. Conclusions This study demonstrates in particular the high relevance of psychological factors for the acceptance and implementation of insulin pump therapy. Structured diabetes education for people with type 1 diabetes and good technical instruction for people who have opted for insulin pump therapy can help to reduce unrealistic expectations and inadequate negative attitudes towards insulin pump therapy. Received: 19 December 2023 Accepted after revision: 08 February 2024 Article published online: 04 October 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Einstellung zur Insulinpumpentherapie bei Menschen mit Typ-1-Diabetes sechs Monate nach Umstellung im Vergleich zu mehrfach täglichen Insulininjektionen – Eine Beobachtungstudie

Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies

Automatische Insulinabgabe-Systeme ("AID-Systeme")

'For me, it didn't seem as drastic a step as being controlled by insulin': A qualitative investigation of expectations and experiences of non-insulin injectable therapy among adults with type 2 diabetes

Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers

Real‐world outcomes of insulin pump compared to injection therapy in a population‐based sample of children with type 1 diabetes

Does insulin pump therapy offer benefits for behaviour, mood, cognition and HbA1c in children and adolescents with type 1 diabetes? A randomised controlled trial with observational follow-up

[Unmet needs in the therapy of type 2 diabetes mellitus. How can barriers to insulin therapy be overcome?]

Availability of and access to continuous subcutaneous insulin infusion therapy for adults with type 1 diabetes in Ireland

Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE)

Diabetes patients' experiences with the implementation of insulin therapy and their perceptions of computer-assisted self-management systems for insulin therapy

Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial

Patient and disease characteristics of adult patients with type 1 diabetes in Germany: an analysis of the DPV and DIVE databases

Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes.

906-P: Audit of Technologies Used for Glucose Monitoring and Insulin Delivery in Patients with Type 1 Diabetes at a Single Diabetes Center during 2019–2022—Real-World Data

Efficacy of an Education Program for People With Diabetes and Insulin Pump Treatment (INPUT): Results From a Randomized Controlled Trial

Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs

Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials

Clinical perspective on innovative insulin delivery technologies in diabetes management

Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group

Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes